Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Holding ASRT?
Track your performance easily
ASRT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $3.40
Previous Close$1.28
Volume503.99K
Average Volume (3M)1.17M
Market Cap
$122.03M
Enterprise Value$72.38M
Total Cash (Recent Filing)$88.38M
Total Debt (Recent Filing)$38.73M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Nov 07, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding95,335,629
10 Day Avg. Volume673,643
30 Day Avg. Volume1,169,388
Standard Deviation0.26
R-Squared0.00130
Alpha0.00825
Financial Highlights & Ratios
Price to Book (P/B)3.71
Price to Sales (P/S)0.89
Price to Cash Flow (P/CF)4.20
P/FCF Ratio3.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.55
Enterprise Value/Gross Profit0.58
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$3.19Price Target Upside149.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Assertio Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAssertio reported 2Q24 revenues of $31.1M, ahead of our estimate of $29.8M and consensus of $30.1M.
Growth PotentialWith its substantial reset in the rearview, an established CEO at the helm, a strong balance sheet, and cash-generating assets, the Company is poised to return to growth.
Market PositionRolvedon has experienced six consecutive quarters of demand growth and is seeing prescriber growth, heavily driving growth currently.
Bears Say
CompetitionThe launch by Zydus of a generic was an unfortunate occurrence for the Company’s self-described unicorn product.
Financial PerformanceIndocin revenues continuing to diminish, and mixed performances from the other portfolio products, acquisitions will be key to sustaining long-term growth.
Revenue DeclineIndocin sales are continuing to decline due to genericization as expected.
---
Ownership Overview
20.83% Insiders
13.92% Mutual Funds
18.11% Other Institutional Investors
47.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $0.73 and its highest was $3.40 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Currently, no data Available
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Nov 07, 2024 which is in 74 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Aug 07, 2024. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.032 by -$0.008.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -$0.04.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 95,335,630 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.032. Following the earnings report the stock price went down -12.195%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is Royce & Associates LLC. It holds Assertio Therapeutics Inc’s shares valued at 94K.
---
Assertio Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.19 (149.22% Upside)
$3.19 (149.22% Upside)
Blogger Sentiment
Bullish
ASRT Sentiment 85%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $35.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.13%
12-Months-Change
Fundamentals
Return on Equity
-178.62%
Trailing 12-Months
Asset Growth
-31.03%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
ASRT Earnings Call
Q2 2024
0:00 / 0:00
---
ASRT Stock 12 Month Forecast
Average Price Target
$3.19
▲(149.22% Upside)
Technical Analysis
Best Analysts Covering ASRT
1 Year
1 Year Success Rate
8/30 ratings generated profit
1 Year Average Return
-26.45%
initiated a buy rating 3 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -26.45% per trade.
---